Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

with services spanning from skin care and hair loss to anxiety and erectile dysfunction. This review examines its erectile dysfunction (ED) services, looking closely at what Hims offers its users ...

Founded in 2017, Hims is a telemedicine platform that offers medical services and treatments related to sexual health, hair loss, anxiety ... from a few dollars per pill to close to $1,000 ...

But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...

Telehealth company Hims & Hers Health (HIMS ... triggering mixed reviews from analysts about the future of its weight loss business. See what stocks are receiving Strong Buy ratings from top ...

Hims & Hers is set to continue offering weight-loss pills and personalized weight-loss support, including nutrition plans and coaching. Outside of weight-loss care, the company saw its subscriber ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Hims & Hers (HIMS) stock took a steep dive ... Instead, the company will focus on weight-loss pills and a generic version of liraglutide — an older GLP-1 drug taken daily instead of weekly ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol. The "Hims and Hers" commercial railed against ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...